Novo Nordisk is the first drugmaker to introduce a highly effective weight loss drug at a time of record obesity rates. The company's share price is up 140% since it launched that drug, Wegovy, in June 2021.
The Danish drugmaker overtook Nestle in March to become Europe's second-most valuable listed company. Jorgensen is navigating the challenge of rapidly ramping up production to meet soaring demand for the breakthrough drugs.
Reuters Breakingviews columnist Aimee Donnellan will discuss Novo Nordisk's new chapter with Jorgensen, a 30-year company veteran and CEO since 2017.
Â
